Ultrasound-Guided Photoacoustic Imaging for the Detection of Metastases in Inguinal Lymph Nodes
Early Phase 1
Active, not recruiting
- Conditions
- Malignant Neoplasm
- Interventions
- Procedure: Fine-Needle AspirationProcedure: Lymph Node BiopsyProcedure: Photoacoustic ImagingProcedure: UltrasoundDevice: Multispectral optoacoustic tomography (MSOT) acuity instrument
- First Posted Date
- 2019-12-04
- Last Posted Date
- 2025-01-10
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 23
- Registration Number
- NCT04185337
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Nasal Inhalation of Isopropyl Alcohol for the Treatment of Nausea in Patients with Cancer
Not Applicable
Not yet recruiting
- Conditions
- Malignant Neoplasm
- Interventions
- First Posted Date
- 2019-11-29
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 112
- Registration Number
- NCT04181463
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Lenvatinib and Pembrolizumab for the Treatment of Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid Cancer
Phase 2
Recruiting
- Conditions
- Poorly Differentiated Thyroid Gland CarcinomaStage IVC Thyroid Gland Anaplastic Carcinoma AJCC v8Stage IVB Thyroid Gland Anaplastic Carcinoma AJCC v8Thyroid Gland Squamous Cell CarcinomaMetastatic Thyroid Gland CarcinomaUnresectable Thyroid Gland Carcinoma
- Interventions
- Drug: LenvatinibBiological: Pembrolizumab
- First Posted Date
- 2019-11-21
- Last Posted Date
- 2024-05-08
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 25
- Registration Number
- NCT04171622
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Acalabrutinib and Venetoclax with or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase 2
Recruiting
- Conditions
- Refractory Small Lymphocytic LymphomaRecurrent Small Lymphocytic LymphomaRecurrent Chronic Lymphocytic LeukemiaRefractory Chronic Lymphocytic Leukemia
- Interventions
- First Posted Date
- 2019-11-20
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 168
- Registration Number
- NCT04169737
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Nelfinavir, Cisplatin, and External Beam Radiation Therapy for the Treatment of Locally Advanced Vulvar Cancer That Cannot Be Removed by Surgery
Phase 1
Recruiting
- Conditions
- Stage IIIB Vulvar Cancer AJCC v8Stage II Vulvar Cancer AJCC v8Stage IIIA Vulvar Cancer AJCC v8Stage IIIC Vulvar Cancer AJCC v8Stage III Vulvar Cancer AJCC v8Stage IVA Vulvar Cancer AJCC v8
- Interventions
- First Posted Date
- 2019-11-20
- Last Posted Date
- 2024-08-26
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 18
- Registration Number
- NCT04169763
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Talabostat and Pembrolizumab for the Treatment of Advanced Solid Cancers
Phase 2
Active, not recruiting
- Conditions
- Advanced Malignant Solid NeoplasmRecurrent Malignant Solid Neoplasm
- Interventions
- First Posted Date
- 2019-11-20
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 15
- Registration Number
- NCT04171219
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Impact of COVID-19 Pandemic on Out-of-Pocket Costs, Lost Wages, and Unemployment in Patients with Breast Cancer Undergoing Breast Surgery
Recruiting
- Conditions
- Breast Ductal Carcinoma in SituCOVID-19 InfectionHereditary Breast CarcinomaInvasive Breast Carcinoma
- Interventions
- Other: Questionnaire Administration
- First Posted Date
- 2019-11-20
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 600
- Registration Number
- NCT04169542
- Locations
- 🇺🇸
MD Anderson in The Woodlands, Conroe, Texas, United States
🇺🇸M D Anderson Cancer Center, Houston, Texas, United States
🇺🇸MD Anderson League City, League City, Texas, United States
Optiflow THRIVE for Delivery of Oxygen to Patients During Total Intravenous Anesthesia While Undergoing Radiology Procedures
Not Applicable
Completed
- Conditions
- Obstructive Sleep Apnea
- Interventions
- Procedure: Oxygen TherapyOther: Questionnaire AdministrationDevice: Optiflow THRIVE
- First Posted Date
- 2019-11-20
- Last Posted Date
- 2024-06-28
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 110
- Registration Number
- NCT04171037
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Venetoclax and Azacitidine for the Treatment of High-Risk Recurrent or Refractory Myelodysplastic Syndrome
Phase 1
Recruiting
- Conditions
- Chronic Myelomonocytic LeukemiaMyelodysplastic SyndromeRecurrent Myelodysplastic SyndromeTherapy-Related Myelodysplastic SyndromeRefractory Myelodysplastic Syndrome
- Interventions
- First Posted Date
- 2019-11-12
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 116
- Registration Number
- NCT04160052
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
High Dose Steroid Therapy (Prednisone or Methylprednisolone) for the Improvement of Symptoms of Late Radiation-Associated Lower Cranial Neuropathy in Oropharyngeal Cancer Survivors
Phase 1
Recruiting
- Conditions
- Cranial Nerve DisorderHead and Neck CarcinomaOropharyngeal Carcinoma
- Interventions
- Drug: MethylprednisoloneDrug: PrednisoneOther: Quality-of-Life AssessmentOther: Questionnaire Administration
- First Posted Date
- 2019-11-05
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 35
- Registration Number
- NCT04151082
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath